Accenture Expands Platform for Drug Discovery and Innovation with Creation of Life Sciences Partner Ecosystem
Summary
NEW YORK & LAS VEGAS--( BUSINESS WIRE )--Accenture (NYSE:ACN) has created an open partner ecosystem designed to help independent software vendors (ISVs) and life sciences companies team more effectively to accelerate drug discovery efforts and, ultimately, improve patient outcomes.“The new ecosystem we’re creating around the Accenture research platform will offer immediate access to innovative tools, enabling life sciences companies to significantly reduce the time, expense and effort required to implement new technology solutions—accelerating drug discovery and delivering solutions to patients faster.”ChemAxon , a provider of highly integrable software with chemical and biological intelligence for the life sciences, flavors, cosmetics, new materials, petro- and agro-chemistry industries; Clarivate Analytics , a global company offering trusted insights and analytics to help companies accelerate the pace of innovation, including a comprehensive suite of solutions for life science professionals; Dotmatics , a company specializing in scientific informatics solutions for the management, query and visualization of chemistry and biology data; SciBite , a provider of text mining, semantics and data intelligence within the biopharma and biotech industries; Scilligence , a company that delivers cross-platform, mobile cheminformatics and bioinformatics solutions; and Vyasa , a provider of scalable, deep-learning software and analytics for life sciences and healthcare organizations.The new research platform and the ecosystem are just a few of the solutions offered by the Accenture Life Sciences R&D practice to help its clients deliver better outcomes for patients.These solutions include services and platforms focused on building more efficient and effective R&D models and fostering collaboration within the industry, from early-stage research to regulatory approval and throughout the product lifecycle.